Volume 8 Supplement 1
Upregulation of inflammatory genes and downregulation of sclerostin are key elements for fracture healing
- J Caetano-Lopes1,
- A Lopes1,
- A Rodrigues1, 2,
- D Fernandes1,
- I P Perpétuo1,
- T Monjardino3, 4,
- R Lucas3, 4,
- J Monteiro5,
- Y T Konttinen6,
- H Canhão†1, 2 and
- J E Fonseca†1, 2
© Fonseca et al; licensee BioMed Central Ltd. 2010
Published: 25 November 2010
Fracture healing is orchestrated by a specific set of events that culminates in the repair of bone and reachievement of its biomechanical properties. The aim of our work was to study the sequence of gene expression events involved in inflammation and bone remodeling occurring in the early phases of callus formation in osteoporotic patients.
Fifty-six patients submitted to hip replacement surgery after a low-energy hip fracture were enrolled in this study. The patients were stratified according to the time interval between fracture and surgery: bone collected within 3 days after fracture (n=13); between the 4th and 7th day (n=33); and after one week from the fracture (n=10). Inflammation- and bone metabolism-related genes were assessed in trabecular bone.
The expression of pro-inflammatory cytokines was increased in the first days after fracture. The genes responsible for bone formation and resorption were upregulated one week after fracture. The increase in RANKL expression occurred just before that, between the 4th-7th days after fracture. Sclerostin expression diminished during the first days after fracture.
The expression of inflammation-related genes is highest at the very first days after fracture but from day 4 onwards there is a shift towards bone remodeling genes, suggesting that the inflammatory phase triggers bone healing. We propose that an initial inflammatory stimulus and a decrease in sclerostin-related effects are the key components in fracture healing. Local promotion of these two events might constitute a promising medical intervention to accelerate fracture healing.
This article is published under license to BioMed Central Ltd.